RESEARCH TRIANGLE PARK, N.C., Nov. 18 /PRNewswire-FirstCall/ -- Incara Pharmaceuticals Corporation (BULLETIN BOARD: INCR) announced that animal results for its catalytic antioxidant compound, AEOL 10150, in development for treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) will be presented at the 14th International Symposium on ALS/MND (motor neuron disease) in Milan, Italy. John P. Crow, Ph.D., Professor of Pharmacology and Toxicology at the University of Arkansas College of Medicine, will make the presentation at the joint closing session of the conference on Wednesday afternoon, November 19. In recent experiments conducted by Dr. Crow in a transgenic mouse model of ALS, the survival time period after symptom onset for the AEOL 10150-treated group of mice was over 2.5 times the survival period of the control group.
Data from these experiments can be viewed at Incara's website http://www.incara.com/ .
"Dr. Crows preclinical findings encourage us to move AEOL 10150 forward as a treatment for ALS," stated Clayton I. Duncan, Chairman and CEO of Incara. "Not only is the animal data impressive, it is robust. Since he first presented his results in September, Dr. Crow has repeated the experiment, which has now been conducted four times with similar results, including most recently using the same route of administration planned for clinical trials."
ALS, the most common motor neuron disease, results from progressive degeneration of both upper and lower motor neurons and is usually fatal within 5 years. Assuming satisfactory completion of animal safety studies, and completion of the remaining components of its recently announced financing, Incara intends to file an IND application for the treatment of ALS in the second quarter of 2004. Allowance of the IND by the FDA would permit Incara to initiate clinical trials. The clinical program will test the ability of AEOL 10150 treatment to extend the survival of ALS patients. Incara has been granted orphan drug designation by the FDA for AEOL 10150 for the treatment of ALS.
Incara Pharmaceuticals Corporation is developing a new class of small molecule catalytic antioxidants that destroy oxygen-derived free radicals, believed to be an important contributor to the pathogenesis of many diseases. Incara's catalytic antioxidants have been shown to reduce damage to tissue in animal studies of neurological disorders such as amyotrophic lateral sclerosis (Lou Gehrig's disease) and stroke, and in other non-neurological indications such as cancer radiation therapy, chronic bronchitis and asthma.
The statements in this press release that are not purely statements of historical fact are forward-looking statements, and actual results might differ materially from those anticipated. These statements and other statements made elsewhere by Incara or its representatives, which are identified or qualified by words such as "intends," "likely," "will," "suggests," "expects," "might," "may," "believe," "could," "should," "would," "anticipates," "plans," or the negative of those terms or similar expressions, are based on a number of assumptions that are subject to risks and uncertainties. Important factors that could cause results to differ include risks associated with the uncertainties of clinical trials, product development activities and scientific research and the need to conserve and obtain funds for operations. These and other important risks are described in Incara's reports on Form 10-K, Form 10-Q and Form 8-K and its registration statements filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Incara assumes no obligation to update the information in this release.
Incara Pharmaceuticals Corporation